First AD Patient Dosed in Lynk Pharmaceuticals' Phase Ib Clinical Study of Topical JAK Inhibitor

LNK01004 ointment is a topical JAK inhibitor, primarily acting on the skin with rapid onset of action and minimal systemic exposure.

The first atopic dermatitis (AD) patient has been dosed in a Phase Ib clinical trial of LNK01004, Lynk Pharmaceuticals Co., Ltd.

The trial was designed to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of LNK01004 ointment in Chinese patients with mild to moderate atopic dermatitis.

LNK01004 ointment is a topical JAK inhibitor, primarily acting on the skin with rapid onset of action and minimal systemic exposure. It has the potential to be a first-in-class treatment with skin-restricted properties. LNK01004 ointment has completed Phase I clinical trials in healthy subjects, demonstrating a good safety profile. Phase Ib clinical trials for the treatment of psoriasis are currently underway.

LNK01004 ointment has shown promising efficacy in preclinical studies, and good safety results in the healthy volunteer study,” says Dr. Henry Wu, Chief Development Officer of Lynk Pharmaceuticals, in a news release. "Atopic dermatitis is a chronic disease with a protracted course of symptoms We believe it has the potential to be a better treatment for patients with atopic dermatitis. We are actively advancing the clinical development of this program and look forward to its performance in patient trials."